Allergan Aesthetics Welcomes Luminera’s Dermal Filler Portfolio

Luminera’s portfolio includes a line of HA dermal fillers, (CaHA)-based fillers, and HArmonyCa, a filler which consists of a combination of cross-linked HA embedded with CaHA microspheres. // Photo Credit: Vagengeym_Elena/iStock/Getty Images (Vagengeym_Elena/iStock/Getty Images)

Allergan Aesthetics, an AbbVie company, has acquired the full dermal filler portfolio and R&D pipeline of Luminera, an Israel-based and privately held esthetics company. "The addition of the Luminera assets adds innovative technology, complementing our leading Juv Derm filler franchise,” says Carrie Strom, senior vice president of AbbVie and president of Global Allergan Aesthetics. “We welcome the Luminera team as we continue to build our global aesthetics company and a world-class product offering for healthcare professionals and patients around the world.” Luminera’s portfolio includes a line of hyaluronic acid (HA) dermal fillers, calcium hydroxyapatite (CaHA)-based fillers, and HArmonyCa, a filler which consists of a combination of cross-linked HA embedded with CaHA microspheres. HArmonyCa, which is designed for the augmentation of facial soft tissue, is currently commercially available inIsrael and Brazil, and Allergan Aesthetics is preparing the product to be released both internationally and in the U.S.

 

RELATED STORIES

Allergan Supports STEM Education for Future Female Leaders

FDA Approves Juvéderm Voluma XC for Chin Enhancement

The Allergan Foundation Donates $2 Million